Cat # PKI-SU11274-005
-
Upload
winifred-gentry -
Category
Documents
-
view
17 -
download
1
description
Transcript of Cat # PKI-SU11274-005
Cat
# P
KI-
SU
11
274
-00
5
SU 11274
Size: 5.0 mgM.W.=568.09Batch No.: 1A/20050309
15875 Gaither Drive
Gaithersburg, MD 20877
FAX. 301-560-4919
TEL. 301-330-5966
Email: [email protected]
Web: www.signagenlabs.com
Description:
SU11274 is a ATP-competitive small molecule inhibitor of the catalytic activity of Met which exhibited a selectivity for Met enzyme versus a panel of other tyrosine kinases (Met IC50 = 0.02 µM, Flk IC50 = 1.3, EGFR IC50 = >100 µM, PDGFßR IC50 = >20 µM, Tie2 IC50 = >100 µM, c-src IC50 = >10 µM, cdk2 IC50 = >10 µM, FGFR-1 IC50 = 9.7 µM). Inhibition of the Met kinase activity by SU11274 led to time- and dose-dependent reduced cell growth and induced G1 cell cycle arrest and apoptosis.
Physical and Chemical Properties:
Molecular Formula: C28H30CIN5O4S Molecular Weight: 568.09Physical appearance: orange solid powderMolecular Structure:
Solubility: DMSO 10 mg/ml at 60 °C.
Stability and Solubility Advice:
Some solutions can be difficult to obtain and can beencouraged by rapid stirring, sonication or gentle warming(in a 45-60°C water bath).
Information concerning product stability, particularly insolution, has rarely been reported and in most cases wecan only offer a general guide. Our standardrecommendations are:
SOLIDS: Provided storage is as stated on the product labeland the vial is kept tightly sealed, the product can be storedfor up to 6 months from date of receipt.
SOLUTIONS: We recommend that stock solutions, onceprepared, are stored aliquoted in tightly sealed vials at -20 0C or below and used within 1 month. Wherever possiblesolutions should be made up and stored on the same day.
This product is for laboratory research ONLY and not for diagnostic use
2
006
Sig
na
Ge
n L
abo
rato
rie
s
References:1. Sattler M, Pride YB, Ma P, Gramlich JL, Chu SC, Quinnan LA, Shirazian S, Liang C, Podar K, Christensen JG, Salgia R. (2003) " A novel small molecule met inhibitor induces apoptosis in cells transformed by the oncogenic TPR-MET tyrosine kinase." Cancer Res. 63(17):5462-9.2. Berthou S, Aebersold DM, Schmidt LS, Stroka D, Heigl C, Streit B, Stalder D, Gruber G, Liang C, Howlett AR, Candinas D, Greiner RH, Lipson KE, Zimmer Y. (2004) " The Met kinase inhibitor SU11274 exhibits a selective inhibition pattern toward different receptor mutated variants." Oncogene.23(31):5387-93.3. Ma PC, Jagadeeswaran R, Jagadeesh S, Tretiakova MS, Nallasura V, Fox EA, Hansen M, Schaefer E, Naoki K, Lader A, Richards W, Sugarbaker D, Husain AN, Christensen JG, Salgia R. (2005) " Functional expression and mutations of c-Met and its therapeutic inhibition with SU11274 and small interfering RNA in non-small cell lung cancer" Cancer Res., 65(4):1479-884. Puri N, Ahmed S, Janamanchi V, Tretiakova M, Zumba O, Krausz T, Jagadeeswaran R, Salgia R. (2007) " c-Met is a potentially new therapeutic target for treatment of human melanoma." Clin Cancer Res;13(7):2246-53.
Storage: Upon arrival store this product at 4 0C.
For long term, store the product at -20 0C. Produc
t shipped at ambient temperature.